Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating activities:
Net income (loss)	$ 186,775	$ (27,347)
Adjustment to reconcile net income (loss) to net cash used in operating activities
Depreciation	84	38
Share-based compensation expense	4,439	1,559
Loss on common stock warrant liabilities	1,516	367
Derivative gain	(258,872)	0
Derivative settlements	4,905	0
Amortization of right-of-use assets	1,324	258
Loss on extinguishment of debt	7,440	0
Amortization of debt issuance costs	16,388	0
Other	98	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,104)	(421)
Accounts payable	3,466	815
Operating lease liabilities	(668)	(290)
Accrued expenses and other liabilities	5,384	1,836
Net cash used in operating activities	(28,825)	(23,185)
Investing activities:
Acquisition of property, plant and equipment	(790,332)	(21,528)
Acquisition of other non-current assets	(6,033)	(1,875)
Net cash used in investing activities	(796,365)	(23,403)
Financing activities:
Proceeds from debt issuance	768,881	0
Receipt of equity commitments	194,627	0
Repayment of debt	(176,000)	0
Costs associated with repayment of debt	(995)	0
Proceeds from sale of common stock	0	35,000
Debt and equity issuance costs	(4,309)	0
Preferred stock dividends	0	(13)
Shares repurchased related to share-based compensation	(94)	(47)
Net cash provided by financing activities	782,110	34,940
Net decrease in cash, cash equivalents and restricted cash	(43,080)	(11,648)
Cash, cash equivalents and restricted cash – beginning of period	294,478	62,789
Cash, cash equivalents and restricted cash – end of period	251,398	51,141
Balance per Consolidated Balance Sheets:
Cash and cash equivalents	45,753
Restricted cash	205,645
Total cash, cash equivalents and restricted cash	$ 251,398	$ 51,141